GLP-1 drugsHumans

Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study

Figure 1. Conceptual model and interpretation framework.
Open the figure at full size
Figure 1. Conceptual model and interpretation framework.Conceptual model and interpretation framework.Lee et al. · CC BY

Biomedicines

Abstract

Background/Objectives: Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists are used long term for obesity and diabetes, but their oesophageal safety is uncertain: weight loss may reduce Barrett's oesophagus and adenocarcinoma risk, wherea

The paper

Samsung Medical Center

Biomedicines · 24 Aug 2026 · CC BY

doi.org/10.3390/biomedicines14091887PubMed 42792631

Related